Discovering Neuroprotection in Parkinson's Disease, or Getting to Haphazard

被引：2

作者：

Kieburtz, Karl ^{[1
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

来源：

MOUNT SINAI JOURNAL OF MEDICINE | 2010年 / 77卷 / 06期

基金：

美国国家卫生研究院;

关键词：

Clinical trials; neuroprotection; Purkinson's disease; URATE; PREDICTOR;

D O I：

10.1002/msj.20219

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite significant research efforts, a therapy to slow cm halt the progression of Parkinson's disease ("neuropiotection") remains elusive The discovery of such a therapy will likely require import-it observations from a number of perspectives basic science investigation, clinical research, and careful observation in medical practice Any possible insights will require. confirmation in rigorous clinical trial testing Combining the useful insights from all perspectives may he the most promising approach to neuroprotective a neuroprotective therapy Mt Sinai Med 77700-706, 2010 (C) 2010 Mown Sinai School of Medicine

引用

页码：700 / 706

页数：7

共 11 条

[1] Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio, Alberto
LeWitt, Peter A.
Xu, Kui
Eberly, Shirley
Watts, Arthur
Matson, Wayne R.
Marras, Connie
Kieburtz, Karl
Rudolph, Alice
Bogdanov, Mikhail B.
Schwid, Steven R.
Tennis, Marsha
Tanner, Caroline M.
Beal, M. Flint
Lang, Anthony E.
Oakes, David
Fahn, Stanley
Shoulson, Ira
Schwarzschild, Michael A.
[J]. ARCHIVES OF NEUROLOGY, 2009, 66 (12) : 1460 - 1468
[2] 'Rejuvenation' protects neurons in mouse models of Parkinson's disease
Chan, C. Savio
Guzman, Jaime N.
Ilijic, Ema
Mercer, Jeff N.
Rick, Caroline
Tkatch, Tatiana
Meredith, Gloria E.
Surmeier, D. James
[J]. NATURE, 2007, 447 (7148) : 1081 - U5
[3] Serum uric acid levels and the risk of Parkinson disease
de Lau, LML
Koudstaal, PJ
Hofman, A
Breteler, MMB
[J]. ANNALS OF NEUROLOGY, 2005, 58 (05) : 797 - 800
[4] Dorsey ER, 2006, ANN NEUROL, V60, pS64
[5] Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy
Kieburtz, Karl
Olanow, C. Warren
[J]. MOUNT SINAI JOURNAL OF MEDICINE, 2007, 74 (01): : 7 - 14
[6] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Lynch, TJ
Bell, DW
Sordella, R
Gurubhagavatula, S
Okimoto, RA
Brannigan, BW
Harris, PL
Haserlat, SM
Supko, JG
Haluska, FG
Louis, DN
Christiani, DC
Settleman, J
Haber, DA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2129 - 2139
[7] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Mok, Tony S.
Wu, Yi-Long
Thongprasert, Sumitra
Yang, Chih-Hsin
Chu, Da-Tong
Saijo, Nagahiro
Sunpaweravong, Patrapim
Han, Baohui
Margono, Benjamin
Ichinose, Yukito
Nishiwaki, Yutaka
Ohe, Yuichiro
Yang, Jin-Ji
Chewaskulyong, Busyamas
Jiang, Haiyi
Duffield, Emma L.
Watkins, Claire L.
Armour, Alison A.
Fukuoka, Masahiro
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) : 947 - 957
[8] TCH346 as a neuroprotective drug in Parkinson"s disease: a double-blind, randomised, controlled trial
Olanow, C. Warren
Schapira, Anthony H. V.
LeWitt, Peter A.
Kieburtz, Karl
Sauer, Dirk
Olivieri, Gianfranco
Pohlmann, Harald
Hubble, Jean
[J]. LANCET NEUROLOGY, 2006, 5 (12) : 1013 - 1020
[9] Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
Schwarzschild, Michael A.
Schwid, Steven R.
Marek, Kenneth
Watts, Arthur
Lang, Anthony E.
Oakes, David
Shoulson, Ira
Ascherio, Alberto
[J]. ARCHIVES OF NEUROLOGY, 2008, 65 (06) : 716 - 723
[10] Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
Shoulson, Ira
Schwid, Steven
Hyson, Christopher
Oakes, David
Gorbold, Emily
Rudolph, Alice
Shinaman, Aileen
Kamp, Cornelia
Kieburtz, Karl
Lang, Anthony
Fahn, Stanley
Gauger, Lisa
Goetz, Christopher
Marek, Kenneth
Seibyl, John
[J]. NEUROLOGY, 2007, 69 (15) : 1480 - 1490

← 1 2 →